Non-animal drug testing in India: A cost-effective and scientifically sound approach

India's pharmaceutical industry is shifting towards non-animal testing methods (NAMs) to reduce drug development costs and timelines. A report by Dr Reddy's Laboratories and other stakeholders found that NAMs can cut drug development timelines by over half and costs by 70-90%. The report highlights the potential of NAMs in biosimilars, which can now be developed for $8-10 million within 24 months without animal testing. The shift is expected to improve drug safety and efficacy while reducing costs.